Functional Imaging of Triple-Negative Breast Cancer and Identification of Biomarkers to Predict Response to Combined Targeted Therapy Jennifer M. Specht, M.D., Principal Investigator University of Washington Medicine Seattle, Washington
Triple-negative breast cancer (TNBC) is an aggressive cancer, which often recurs and may be resistant to chemotherapy. Survival for these patients is poorer than for other types of breast cancer. Patients with metastatic or Stage IV TNBC will be treated with a drug that targets blood vessel growth, and tumors will be evaluated before therapy, after two weeks of therapy, and after six months of therapy using PET and MRI scans. In this study, Dr. Specht will look at certain proteins (biomarkers) to determine whether this therapy works better than other traditional chemotherapies in patients with certain characteristics.